Trial Outcomes & Findings for Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048 (NCT NCT00157248)
NCT ID: NCT00157248
Last Updated: 2014-05-19
Results Overview
Time to first occurrence of stroke, transient ischaemic attacks, system thromboembolism, myocardial infarction, other major adverse cardiac events and mortality. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Recruitment status
TERMINATED
Study phase
PHASE2
Target enrollment
361 participants
Primary outcome timeframe
5 years
Results posted on
2014-05-19
Participant Flow
This was a non-randomized open-label extension study of study 1160.20. Patients initially continued Dabigatran treatment of 1160.20; per protocol amendment, most patients moved to 150 mg bid. All events were assigned to the Dabigatran regimen that a patient received prior to the event and patients may be counted in multiple regimens
In this non-randomized follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study.
Participant milestones
| Measure |
Dabigatran Etexilate, 150 mg QD (Once Daily)
Dosage used at study start
|
Dabigatran Etexilate, 150 mg BID (Twice Daily)
Dosage used at study start
|
Dabigatran Etexilate, 300 mg QD (Once Daily)
Dosage used at study start
|
Dabigatran Etexilate, 300 mg BID (Twice Daily)
Dosage used at study start
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
98
|
89
|
50
|
124
|
|
Overall Study
COMPLETED
|
50
|
52
|
29
|
77
|
|
Overall Study
NOT COMPLETED
|
48
|
37
|
21
|
47
|
Reasons for withdrawal
| Measure |
Dabigatran Etexilate, 150 mg QD (Once Daily)
Dosage used at study start
|
Dabigatran Etexilate, 150 mg BID (Twice Daily)
Dosage used at study start
|
Dabigatran Etexilate, 300 mg QD (Once Daily)
Dosage used at study start
|
Dabigatran Etexilate, 300 mg BID (Twice Daily)
Dosage used at study start
|
|---|---|---|---|---|
|
Overall Study
Adverse Event
|
36
|
25
|
13
|
33
|
|
Overall Study
Protocol Violation
|
4
|
0
|
2
|
2
|
|
Overall Study
Lost to Follow-up
|
0
|
1
|
0
|
0
|
|
Overall Study
Withdrawal by Subject
|
1
|
4
|
3
|
3
|
|
Overall Study
site closures, subject moving
|
7
|
7
|
3
|
9
|
Baseline Characteristics
Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048
Baseline characteristics by cohort
| Measure |
Dabigatran Etexilate, 150 mg QD (Once Daily)
n=98 Participants
Dosage used at study start
|
Dabigatran Etexilate, 150 mg BID (Twice Daily)
n=89 Participants
Dosage used at study start
|
Dabigatran Etexilate, 300 mg QD (Once Daily)
n=50 Participants
Dosage used at study start
|
Dabigatran Etexilate, 300 mg BID (Twice Daily)
n=124 Participants
Dosage used at study start
|
Total
n=361 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Continuous
|
70.4 Years
STANDARD_DEVIATION 8.6 • n=5 Participants
|
69.3 Years
STANDARD_DEVIATION 8.2 • n=7 Participants
|
71.0 Years
STANDARD_DEVIATION 6.8 • n=5 Participants
|
68.8 Years
STANDARD_DEVIATION 8.5 • n=4 Participants
|
69.7 Years
STANDARD_DEVIATION 8.2 • n=21 Participants
|
|
Sex: Female, Male
Female
|
19 Participants
n=5 Participants
|
18 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
12 Participants
n=4 Participants
|
59 Participants
n=21 Participants
|
|
Sex: Female, Male
Male
|
79 Participants
n=5 Participants
|
71 Participants
n=7 Participants
|
40 Participants
n=5 Participants
|
112 Participants
n=4 Participants
|
302 Participants
n=21 Participants
|
|
Atrial fibrillation
Persistent
|
40 Participants
139 • n=5 Participants
|
38 Participants
40 • n=7 Participants
|
15 Participants
38 • n=5 Participants
|
46 Participants
15 • n=4 Participants
|
139 Participants
n=21 Participants
|
|
Atrial fibrillation
Permanent
|
40 Participants
n=5 Participants
|
28 Participants
n=7 Participants
|
25 Participants
n=5 Participants
|
47 Participants
n=4 Participants
|
140 Participants
n=21 Participants
|
|
Atrial fibrillation
Paroxysmal
|
18 Participants
n=5 Participants
|
23 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
31 Participants
n=4 Participants
|
82 Participants
n=21 Participants
|
PRIMARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to first occurrence of stroke, transient ischaemic attacks, system thromboembolism, myocardial infarction, other major adverse cardiac events and mortality. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate for Composite Endpoint of Stroke, Transient Ischaemic Attacks, System Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and Mortality.
|
0.0 yearly event rate (percentage)
|
17.0 yearly event rate (percentage)
|
5.0 yearly event rate (percentage)
|
5.7 yearly event rate (percentage)
|
4.5 yearly event rate (percentage)
|
2.4 yearly event rate (percentage)
|
PRIMARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to first occurrence of fatal or life-threatening, retroperitoneal, intracranial, intraocular, or intraspinal bleeding, which required surgical treatment, led to a transfusion of a minimum of 2 units of packed cells or whole blood, or led to a fall in hemoglobin of 20g/L or less. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate for Major Bleeding
|
0.0 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
6.6 yearly event rate (percentage)
|
3.1 yearly event rate (percentage)
|
0.8 yearly event rate (percentage)
|
7.3 yearly event rate (percentage)
|
PRIMARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to first occurrence of either major or minor/relevant bleeding. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate for Major + Minor/Relevant Bleeding
|
0.0 yearly event rate (percentage)
|
8.5 yearly event rate (percentage)
|
11.6 yearly event rate (percentage)
|
7.6 yearly event rate (percentage)
|
6.6 yearly event rate (percentage)
|
26.8 yearly event rate (percentage)
|
PRIMARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to first occurrence of any bleeding event. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate for Any Bleeding
|
0.0 yearly event rate (percentage)
|
25.5 yearly event rate (percentage)
|
21.5 yearly event rate (percentage)
|
14.7 yearly event rate (percentage)
|
14.9 yearly event rate (percentage)
|
58.5 yearly event rate (percentage)
|
PRIMARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to first occurrence of minor bleeding. A minor bleeding event is any bleed that does not qualify as a major bleed. All minor bleeding events not fulfilling one of the criteria for clinically relevant were classified as nuisance bleeds. Clinically-relevant was defined as spontaneous skin hematoma ≥25 cm², spontaneous nose bleed \>5 min, macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention, spontaneous rectal bleeding, gingival bleeding \>5 min, leading to hospitalization, leading to a transfusion of \<2 units of packed cells or whole blood and any other bleeding event considered clinically relevant by the investigator. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate for Minor Bleeding
Nuisance only
|
0.0 yearly event rate (percentage)
|
17.0 yearly event rate (percentage)
|
9.9 yearly event rate (percentage)
|
7.1 yearly event rate (percentage)
|
8.3 yearly event rate (percentage)
|
31.7 yearly event rate (percentage)
|
|
Yearly Event Rate for Minor Bleeding
Clinically relevant
|
0.0 yearly event rate (percentage)
|
8.5 yearly event rate (percentage)
|
5.0 yearly event rate (percentage)
|
4.5 yearly event rate (percentage)
|
5.8 yearly event rate (percentage)
|
19.5 yearly event rate (percentage)
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to first occurrence of any fatal or non-fatal stroke. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate for Stroke
|
0.0 yearly event rate (percentage)
|
4.3 yearly event rate (percentage)
|
5.0 yearly event rate (percentage)
|
1.1 yearly event rate (percentage)
|
1.7 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to first occurrence of any ischaemic stroke. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate of Ischaemic Stroke
|
0.0 yearly event rate (percentage)
|
4.3 yearly event rate (percentage)
|
5.0 yearly event rate (percentage)
|
0.5 yearly event rate (percentage)
|
1.7 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to first occurrence of any haemorrhagic stroke. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate of Haemorrhagic Stroke
|
0.0 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
0.6 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to first occurrence of any transient ischaemic attacks. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate for Transient Ischaemic Attacks
|
0.0 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
0.2 yearly event rate (percentage)
|
0.4 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to first occurrence of any non-central nervous system systemic thromboembolism. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate for Systemic Thromboembolism
|
0.0 yearly event rate (percentage)
|
8.5 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
0.2 yearly event rate (percentage)
|
0.4 yearly event rate (percentage)
|
1.2 yearly event rate (percentage)
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to first occurrence of any myocardial infarction. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate of Myocardial Infarction
|
0.0 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
1.1 yearly event rate (percentage)
|
0.4 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to first occurrence of any other major adverse cardiac events. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate of Other Major Adverse Cardiac Events
|
0.0 yearly event rate (percentage)
|
8.5 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
1.1 yearly event rate (percentage)
|
0.8 yearly event rate (percentage)
|
1.2 yearly event rate (percentage)
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to death of any cause. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate of Death
|
0.0 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
2.7 yearly event rate (percentage)
|
2.1 yearly event rate (percentage)
|
0.0 yearly event rate (percentage)
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: All treated patients. In this non-randomized follow-up study, most patients changed treatment regimens per amendment during conduct and treatment exposure was not comparable between regimens. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens. No statistical analysis was done.
Time to first occurrence of ischaemic stroke, transient ischaemic attacks, non-central nervous system systemic thromboembolism, myocardial infarction, other major adverse cardiac events and all-cause mortality. Yearly event rate (%) = number of subjects with event / subject-years \* 100. Subject years = sum (date of end of treatment - date of start of treatment) of all entered subjects / 365.25
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Yearly Event Rate for Composite Secondary Endpoint of Ischaemic Stroke, Transient Ischaemic Attacks, Non-central Nervous System Systemic Thromboembolism, Myocardial Infarction, Other Major Adverse Cardiac Events and All-cause Mortality
|
0.0 yearly event rate (percentage)
|
17.0 yearly event rate (percentage)
|
5.0 yearly event rate (percentage)
|
5.5 yearly event rate (percentage)
|
4.5 yearly event rate (percentage)
|
2.4 yearly event rate (percentage)
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: All treated patients.
Frequency of patients with severe adverse events.
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Severe Adverse Event
|
0 participants
|
5 participants
|
13 participants
|
96 participants
|
28 participants
|
16 participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: All treated patients.
Frequency of patients with possible clinically significant abnormalities, i.e. with values out of normal range. Normal ranges are defined as: * Alanine aminotransferase (ALT): 5-45 \[U/L\] * Aspartate aminotransferase (AST): 10-40 \[U/L\] * Bilirubin, total: 0.2-1.0 \[mg/dL\]
Outcome measures
| Measure |
50 mg Once Daily
n=1 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 Participants
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 Participants
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 Participants
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Laboratory Analyses
Bilirubin > 2*ULN
|
0 participants
|
0 participants
|
0 participants
|
5 participants
|
2 participants
|
0 participants
|
|
Laboratory Analyses
AST > 3*ULN
|
0 participants
|
0 participants
|
0 participants
|
10 participants
|
3 participants
|
1 participants
|
|
Laboratory Analyses
ALT > 3*ULN
|
0 participants
|
0 participants
|
0 participants
|
9 participants
|
4 participants
|
2 participants
|
Adverse Events
50 mg Once Daily
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
50 mg Twice Daily
Serious events: 8 serious events
Other events: 18 other events
Deaths: 0 deaths
150 mg Once Daily
Serious events: 20 serious events
Other events: 17 other events
Deaths: 0 deaths
150 mg Twice Daily
Serious events: 153 serious events
Other events: 219 other events
Deaths: 0 deaths
300 mg Once Daily
Serious events: 39 serious events
Other events: 65 other events
Deaths: 0 deaths
300 mg Twice Daily
Serious events: 21 serious events
Other events: 57 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
50 mg Once Daily
n=1 participants at risk
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 participants at risk
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 participants at risk
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 participants at risk
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 participants at risk
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 participants at risk
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Small intestinal obstruction
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Asthenia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Chest discomfort
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Chest pain
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.9%
14/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.2%
2/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Drug ineffective
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Dysplasia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Fatigue
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
General physical health deterioration
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Impaired healing
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Influenza like illness
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Malaise
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Oedema peripheral
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Pyrexia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Sudden cardiac death
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Sudden death
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Hepatobiliary disorders
Bile duct stone
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Hepatobiliary disorders
Cholecystitis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Hepatobiliary disorders
Cholecystitis acute
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.2%
2/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Hepatobiliary disorders
Hepatic function abnormal
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Appendicitis perforated
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Arthritis bacterial
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Endocarditis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Erysipelas
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Gangrene
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Implant site infection
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Infected skin ulcer
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Infective exacerbation of chronic obstructive airways disease
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.5%
9/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Acute coronary syndrome
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.4%
5/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Angina unstable
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.7%
6/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Aortic valve stenosis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Arrhythmia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Atrial conduction time prolongation
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.4%
12/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.3%
3/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.2%
2/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Atrial flutter
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Atrial thrombosis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Atrioventricular block complete
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.7%
6/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.2%
2/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Cardiac asthma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.0%
2/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.9%
14/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
7.8%
7/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.0%
2/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.3%
3/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Cardio-respiratory arrest
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Cardiogenic shock
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Conduction disorder
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Cor pulmonale
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Coronary artery disease
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Coronary artery stenosis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Mitral valve incompetence
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.0%
7/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Myocardial ischaemia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Pericardial effusion
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Sick sinus syndrome
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Ventricular arrhythmia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Ventricular fibrillation
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Ventricular tachycardia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
4/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Eye disorders
Cataract
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Eye disorders
Retinal detachment
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Eye disorders
Retinal haemorrhage
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Abdominal adhesions
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Crohn's disease
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Diverticulum
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Diverticulum intestinal
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Duodenal ulcer haemorrhage
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Gastric haemorrhage
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Gastric ulcer
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Faeces discoloured
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.2%
2/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Inguinal hernia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.0%
7/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Intestinal ischaemia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Intestinal obstruction
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Melaena
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
4/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Oesophageal ulcer
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Oesophagitis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Pancreatic pseudocyst
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Peritonitis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Social circumstances
Joint prosthesis user
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Surgical and medical procedures
Cardiac pacemaker replacement
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Lobar pneumonia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Localised infection
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Meningitis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Nail infection
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
4.2%
15/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.2%
2/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Post procedural infection
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Sepsis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Skin infection
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Urosepsis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Wound infection
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Ankle fracture
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Chest injury
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Femur fracture
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Gastrointestinal stoma complication
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Implantable defibrillator malfunction
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Incisional hernia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Postoperative ileus
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Radius fracture
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Rib fracture
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Skin laceration
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Stent-graft endoleak
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Subdural haematoma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Tendon rupture
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Wrist fracture
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Investigations
Blood creatinine increased
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Investigations
Blood pressure systolic inspiratory decreased
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Investigations
Electrocardiogram ST segment depression
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Investigations
Haemoglobin decreased
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Investigations
Heart rate increased
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Investigations
Heart rate irregular
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Investigations
Hepatic enzyme increased
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Investigations
Liver function test abnormal
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Gouty arthritis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Lumbar spinal stenosis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Osteitis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
4/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer recurrent
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder papilloma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.2%
2/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bronchial carcinoma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer metastatic
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung cancer metastatic
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bone
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lymph nodes
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Multiple myeloma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm skin
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Cerebral haemorrhage
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Cerebral infarction
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Cerebrovascular accident
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.7%
6/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.2%
2/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Epilepsy
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Surgical and medical procedures
Hip arthroplasty
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Haemorrhage intracranial
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Haemorrhagic stroke
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Hemiparesis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Ischaemic cerebral infarction
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Ischaemic stroke
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.9%
3/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.2%
2/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Loss of consciousness
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Migraine
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Myasthenic syndrome
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Syncope
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.0%
7/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.3%
3/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Transient ischaemic attack
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Psychiatric disorders
Delirium
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Renal and urinary disorders
Albuminuria
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Renal and urinary disorders
Calculus urethral
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Renal and urinary disorders
Renal cyst
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Renal and urinary disorders
Renal failure acute
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Renal and urinary disorders
Renal failure chronic
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Renal and urinary disorders
Renal impairment
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Renal and urinary disorders
Renal infarct
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Renal and urinary disorders
Urethral haemorrhage
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Renal and urinary disorders
Urinary tract disorder
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Reproductive system and breast disorders
Benign prostatic hyperplasia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.4%
5/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Reproductive system and breast disorders
Cystocele
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Reproductive system and breast disorders
Prostatism
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Reproductive system and breast disorders
Rectocele
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Reproductive system and breast disorders
Uterine prolapse
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.4%
5/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.5%
9/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
4.4%
4/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Haemothorax
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Lung infiltration
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary fibrosis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory distress
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Restrictive pulmonary disease
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Skin and subcutaneous tissue disorders
Skin discolouration
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Aneurysm
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Aortic aneurysm
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Aortic aneurysm rupture
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Aortic dissection
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Aortic stenosis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.56%
2/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Circulatory collapse
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Deep vein thrombosis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Femoral artery aneurysm
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Femoral artery occlusion
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Haemorrhage
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Hypertension
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Hypotension
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
4/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Intermittent claudication
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Ischaemia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Peripheral arterial occlusive disease
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Peripheral embolism
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Peripheral ischaemia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Peripheral vascular disorder
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Temporal arteritis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Vasculitis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.28%
1/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Wound haemorrhage
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
Other adverse events
| Measure |
50 mg Once Daily
n=1 participants at risk
Number of Participants treated at any time with 50 mg of Dabigatran etexilate once daily
|
50 mg Twice Daily
n=105 participants at risk
Number of Participants treated at any time with 50 mg of Dabigatran etexilate twice daily
|
150 mg Once Daily
n=102 participants at risk
Number of Participants treated at any time with 150 mg of Dabigatran etexilate once daily
|
150 mg Twice Daily
n=356 participants at risk
Number of Participants treated at any time with 150 mg of Dabigatran etexilate twice daily
|
300 mg Once Daily
n=90 participants at risk
Number of Participants treated at any time with 300 mg of Dabigatran etexilate once daily
|
300 mg Twice Daily
n=161 participants at risk
Number of Participants treated at any time with 300 mg of Dabigatran etexilate twice daily
|
|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.9%
21/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.3%
3/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.2%
2/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Cardiac disorders
Angina pectoris
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.6%
20/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
8.9%
8/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.5%
4/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Eye disorders
Cataract
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.3%
19/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.3%
3/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.9%
2/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.3%
19/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.1%
1/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.5%
4/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.7%
7/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.0%
2/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.9%
14/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
10.0%
9/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
8.6%
9/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.9%
4/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.3%
19/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
4.4%
4/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.7%
6/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.9%
3/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.0%
2/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.2%
22/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.3%
3/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.8%
11/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.9%
3/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.0%
2/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.2%
22/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
11.1%
10/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.7%
6/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Chest pain
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.9%
2/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.1%
18/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.6%
5/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.0%
8/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Fatigue
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.9%
2/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.9%
4/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
11.0%
39/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
13.3%
12/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.2%
10/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
General disorders
Oedema peripheral
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.9%
3/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.9%
6/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
12.9%
46/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
11.1%
10/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.0%
8/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Bronchitis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.0%
2/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
4.8%
17/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.6%
5/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.9%
3/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Influenza
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.2%
22/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
10.0%
9/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.8%
11/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.9%
3/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
4.9%
5/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
12.1%
43/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
14.4%
13/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
4.3%
7/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Pneumonia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.0%
2/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.6%
20/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.3%
3/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.9%
2/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.5%
23/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.3%
3/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.2%
2/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Contusion
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.0%
2/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.3%
19/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.3%
3/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.8%
11/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
4.8%
17/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.7%
6/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Injury, poisoning and procedural complications
Wound
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.4%
5/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.7%
6/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.62%
1/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Metabolism and nutrition disorders
Diabetes mellitus
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.9%
3/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.0%
2/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.4%
12/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.6%
5/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.7%
6/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Metabolism and nutrition disorders
Gout
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.9%
3/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.4%
12/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.7%
6/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Metabolism and nutrition disorders
Hypercholesterolaemia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.7%
6/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.7%
6/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.9%
3/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.9%
2/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.9%
3/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.5%
23/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.7%
6/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.5%
4/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.9%
2/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.9%
7/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
7.9%
28/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
14.4%
13/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.9%
3/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.1%
11/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.6%
5/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.2%
2/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.4%
5/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.7%
6/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.2%
2/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.8%
4/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.9%
4/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.1%
18/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
7.8%
7/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.2%
2/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.7%
7/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.9%
4/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
10.1%
36/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
14.4%
13/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
8.7%
14/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Nervous system disorders
Headache
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.7%
6/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.9%
3/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.2%
22/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
7.8%
7/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.1%
5/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.1%
18/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.3%
3/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.2%
2/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Renal and urinary disorders
Haematuria
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.0%
2/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
9.0%
32/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
4.4%
4/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.5%
4/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.7%
6/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.7%
6/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.2%
2/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
4.9%
5/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
8.1%
29/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
16.7%
15/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.6%
9/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.9%
6/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
10.4%
37/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
13.3%
12/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.6%
9/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
2.9%
3/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.5%
23/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
11.1%
10/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
6.8%
11/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.4%
12/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
8.9%
8/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.9%
3/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Haematoma
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.95%
1/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.98%
1/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
4.8%
17/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
11.1%
10/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.7%
6/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Hypertension
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
1.9%
2/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
4.9%
5/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
9.0%
32/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
15.6%
14/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
3.1%
5/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
|
Vascular disorders
Varicose vein
|
0.00%
0/1 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/105 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/102 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.84%
3/356 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
5.6%
5/90 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
0.00%
0/161 • 5 years
All treated patients. In this follow-up study, events are displayed cumulatively that occurred in the initial study (1160.20) or in the present study. Most patients changed treatment regimens per amendment during conduct. Events were assigned to the regimen a patient received prior to the event, and patients may be counted in multiple regimens.
|
Additional Information
Boehringer Ingelheim Call Center
Boehringer Ingelheim Pharmaceuticals
Phone: 1-800-243-0127
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract
- Publication restrictions are in place
Restriction type: OTHER